Increase in sales of ProSense®, based on preliminary unaudited results, demonstrate growing adoption of ProSense® cryoablation for breast tumors. FDA decision on ...

IceCure Medical’s next-generation cryoablation technology to receive European patent: Caesarea, Israel Monday, January 6, 2025, 13:00 Hrs [IST] IceCure Medical Ltd., a developer ...

As a minimally invasive option, cryoablation with ProSense® offers ... IceCure's potential to set a new standard for minimally-invasive procedures. Mr. Lee is the Chairman of VI Asset Management ...

According to the United Nations, soil salinization affects between 20% and 40% of arable land globally, with human activity ...

Treatment options for early stages of esophageal cancer have significantly improved over the last decades, with a radical shift in the treatment paradigm from surgery to endoscopic therapy. The aim of ...

IceCure Medical (Nasdaq:ICCM) announced today that it received an intention to grant notice from the European Patent Office.

The ProSense® Cryoablation System is a minimally invasive ... ProSense® opens that door to fast and convenient office-based procedures for breast tumors.

As researchers in Texas and across the U.S. continue to build the case for cryoablation as a part of front-line breast cancer treatment, McArthur and Huang are hopeful the procedure will help ...

XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen ...

An oxygen sensor protein protects the enzymatic machinery of biological nitrogen fixation from serious damage, and its use in ...